{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.2","upperLimit":"45.8","value":"25.9"},{"comment":"Upper limit of 95% confidence interval was not estimable due to low number of participants with event.","groupId":"OG001","lowerLimit":"32.5","upperLimit":"NA","value":"40.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"OS is defined as the time interval from the date of the first dose of the study treatment until death due to any cause. Intracranial OS was calculated by Kaplan-Meier estimation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).","id":"OG000","title":"Brigatinib 90 mg"},{"description":"Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).","id":"OG001","title":"Brigatinib 90 mg - 180 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose.","reportingStatus":"POSTED","timeFrame":"Up to approximately 69 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}